During the past decade, Centro Medico Imbanaco conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 11 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 4 clinical trials were completed. i.e. 36.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro Medico Imbanaco" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "Baxalta now part of Shire" with 3 trials sponsored, "Amgen" with 2 trials sponsored, "Bayer" with 2 trials sponsored and "Janssen Research & Development, LLC" with 2 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro Medico Imbanaco" #1 collaborator was "National Institute of Allergy and Infectious Diseases (NIAID)" with 2 trials as a collaborator, "Children's Hospital of Philadelphia" with 1 trials as a collaborator, "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Latin American Cooperative Oncology Group" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Centro Medico Imbanaco" are "Hemophilia B" (3 trials), "Breast Cancer" (2 trials), "Chemotherapy-induced Thrombocytopenia" (2 trials), "Prostatic Neoplasms" (2 trials) and "Acute Respiratory Failure" (1 trials). Many other conditions were trialed in "Centro Medico Imbanaco" in a lesser frequency.

Most popular intervention types in "Centro Medico Imbanaco" are "Drug" (20 trials), "Biological" (8 trials), "Other" (5 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Docetaxel" (2 trials), "Pembrolizumab" (2 trials), "Romiplostim" (2 trials) and "Abicipar Pegol" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centro Medico Imbanaco" are 25 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Centro Medico Imbanaco". undefined are not yet recruiting, 4 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Centro Medico Imbanaco, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Centro Medico Imbanaco, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".

Centro Medico Imbanaco has several departments that took part in Clinical trials: "Clínica Imbanaco; Oncology" - 5 trials